Tectonic Therapeutic (TECX) Total Non-Current Liabilities (2017 - 2023)
Tectonic Therapeutic (TECX) posted quarterly Total Non-Current Liabilities of $9.7 million for Q4 2025, down 77.63% quarter-over-quarter from $43.4 million in Q4 2023.
Powered by 
Analysis
Tectonic Therapeutic (TECX) Total Non-Current Liabilities (2017 - 2023) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Total Non-Current Liabilities for 3 consecutive years, with $9.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $9.7 million; the TTM figure through Dec 2025 stood at $9.7 million (changed N/A YoY), while the FY2025 annual figure was $9.7 million, changed N/A from the prior year.
- Total Non-Current Liabilities retreated to $9.7 million in Q4 2025 per TECX's latest filing, from $43.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $43.4 million in Q4 2023 and bottomed at $9.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Tectonic Therapeutic | 582.01 Mn | 582.01 Mn | - | - |